Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yana Pikman, M.D.

Co-Author

This page shows the publications co-authored by Yana Pikman and Andrew Place.
Connection Strength

0.723
  1. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 Jun; 11(6):1424-1439.
    View in: PubMed
    Score: 0.237
  2. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
    View in: PubMed
    Score: 0.194
  3. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024.
    View in: PubMed
    Score: 0.176
  4. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885.
    View in: PubMed
    Score: 0.059
  5. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.